Please login to the form below
Blueprint Medicines
This page shows the latest Blueprint Medicines news and features for those working in and with pharma, biotech and healthcare.
Roche pays $775m upfront to access Blueprint’s RET programme
Expands on initial deal that is worth up to $1bn. Roche has expanded its existing collaboration with Blueprint Medicines, signing a new deal which will see it gain rights to the ... development of pralsetinib across multiple treatment settings where
Latest news
-
Revenue growth at Ipsen numbs pain of palovarotene calamity
for Blueprint Medicines’ BLU-782, an ALK2 inhibitor in phase 1 development for the treatment of FOP.
-
US start-up EQRx promises approach that will slash drug prices
in 2018 – and Blueprint Medicines which has just claimed its first approval for a high-priced cancer drug. ... Borisy will serve as both chairman and chief executive of the new company, which like Foundation and Blueprint is based in Cambridge,
-
FDA clears Blueprint’s $32k-per-month GI cancer drug
First product approval for rare targeted therapy. Blueprint Medicines has its first product approval, claiming an FDA green light for Ayvakit as a treatment for gastrointestinal stromal tumours (GIST) caused by ... Blueprint claimed the approval on the
-
Europe’s medicines tracking system goes live
The organisation says that the EMVO system could well serve as a blueprint for securing the supply of medicines beyond Europe. ... The verification of the Unique Identifier and authentication happens in the National Medicines Verification System (NMVS).
-
RET rivals Loxo and Blueprint face off with early-stage data
No clear winner between RET inhibitor rivals. Two companies developing RET inhibitors for cancer – Loxo Oncology and Blueprint Medicines – have gone head-to-head with data readouts that have analysts trying ... Blueprint’s data with its BLU-667
More from news
Approximately 5 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Integrating patient reported outcomes into clinical trials
And Blueprint Medicines created a proprietary PRO for its mastocytosis drug. ... Blueprint Medicines is one company that took matters into its own hands.
-
Spotlight on Patient Engagement
Open Conversations: Pathway to Launch Excellence It is widely acknowledged that yesterday’s playbook no longer provides the best blueprint for launching tomorrow’s medicines.
-
Open Conversations: Pathway to Launch Excellence
Open Conversations: Pathway to Launch Excellence. It is widely acknowledged that yesterday’s playbook no longer provides the best blueprint for launching tomorrow’s medicines.
-
Deal Watch March 2016
Roche has paid $45m upfront with $965m in contingent fees, including options, milestones and royalties for the rights to up to five small molecules from Blueprint Medicines' drug discovery platform. ... Acquisition of royalty rights. $1, 140. Blueprint
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
PMHub
Empowering Strategic Performance Ltd
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
